1.35
InspireMD Inc. stock is traded at $1.35, with a volume of 80,809.
It is up +0.00% in the last 24 hours and down -18.18% over the past month.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms. InspireMD, Inc. distributes its products in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.
See More
Previous Close:
$1.35
Open:
$1.36
24h Volume:
80,809
Relative Volume:
2.21
Market Cap:
$63.18M
Revenue:
$8.98M
Net Income/Loss:
$-48.79M
P/E Ratio:
-1.6939
EPS:
-0.797
Net Cash Flow:
$-36.77M
1W Performance:
-1.46%
1M Performance:
-18.18%
6M Performance:
-43.28%
1Y Performance:
-45.12%
InspireMD Inc. Stock (NSPR) Company Profile
Name
InspireMD Inc.
Sector
Industry
Phone
972 3 6917691
Address
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
NSPR
InspireMD Inc.
|
1.35 | 63.18M | 8.98M | -48.79M | -36.77M | -0.797 |
|
ABT
Abbott Laboratories
|
101.56 | 175.59B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
341.24 | 132.47B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
87.10 | 113.14B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
64.61 | 94.85B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
78.20 | 45.09B | 6.07B | 1.06B | 1.34B | 1.8063 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Initiated | Maxim Group | Buy |
| Jan-07-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-13-15 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-26-13 | Initiated | Oppenheimer | Outperform |
InspireMD Inc. Stock (NSPR) Latest News
InspireMD : April 2026 Investor Deck - marketscreener.com
Shareholder Lawsuit Launched Against InspireMD - National Today
After plunging 15.2% in 4 weeks, here's why the trend might reverse for InspireMD (NSPR) - MSN
Form 424B5Prospectus [Rule 424(b)(5)] - ADVFN
InspireMD (NSPR) asks shareholders to approve 150M→250M share increase - Stock Titan
After Dropping 15.2% Over the Past Four Weeks, This Is Why InspireMD (NSPR) Could See a Turnaround - Bitget
After Plunging 15.2% in 4 Weeks, Here's Why the Trend Might Reverse for InspireMD (NSPR) - Yahoo Finance
InspireMD (NYSE:NSPR) Trading Down 6.7%What's Next? - MarketBeat
Published on: 2026-04-06 18:18:37 - baoquankhu1.vn
InspireMD, Inc. Enters Equity Distribution Agreement with BTIG, LLC – SEC 8-K Filing Details (April 2026) - Minichart
InspireMD Establishes New $75 Million ATM Program - TipRanks
According to the latest submitted documents, medical device company InspireMD Inc. has signed an equity distribution agreement with the sales agent. - Bitget
InspireMD Launches $75 Million At-The-Market Equity Program With BTIG - TradingView — Track All Markets
InspireMD (NSPR) sets $75M BTIG equity distribution agreement - Stock Titan
InspireMD (NSPR) launches up to $75M ATM program with BTIG as agent - Stock Titan
NSPR Technical Analysis & Stock Price Forecast - Intellectia AI
InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference - The Manila Times
InspireMD to Present at 25th Annual Needham Virtual Healthcare Conference - National Today
Stroke-device maker InspireMD will speak at Needham's April 14 webcast - Stock Titan
Stock Market Recap: Is InspireMD Inc stock risky to hold nowMarket Growth Review & Safe Swing Trade Setup Alerts - baoquankhu1.vn
InspireMD Stock Dips On Wider-Than-Expected Q1 Loss, But Retail Is Optimistic - MSN
Published on: 2026-03-28 05:12:59 - baoquankhu1.vn
Market Trends: Will InspireMD Inc stock hit new highs in YEAR2026 Technical Overview & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
CEO Moves: Will InspireMD Inc stock hit new highs in YEAR2026 Sentiment & Proven Capital Preservation Methods - baoquankhu1.vn
InspireMD tops Q4 estimates as revenue jumps, shares rise in premarket trading - MSN
Geopolitics Watch: Can InspireMD Inc keep up with sector leadersMarket Risk Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
InspireMD Q2 2025 Earnings Preview - MSN
InspireMD targets $13M–$15M in 2026 revenue as CGuard Prime gains US traction - MSN
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Johnson & Johnson (JNJ) and InspireMD (NSPR) - The Globe and Mail
InspireMD, Inc. (NSPR) reports Q4 loss, beats revenue estimates - MSN
InspireMD revenue up 62% to USD 3.1M in Q4 2025 - Medical Buyer
Returns Recap: Can InspireMD Inc outperform in the next rallyDay Trade & Safe Entry Trade Reports - baoquankhu1.vn
InspireMD Reports 62% Q4 Revenue Growth and Sets 2026 Outlook for CGuard Prime Carotid Stent System - Minichart
InspireMD’s Growth Hinges on Real CAS Market Size and Physician Adoption - TipRanks
Earnings call transcript: InspireMD Q4 2025: Revenue Surges, EPS Beats By Investing.com - za.investing.com
InspireMD earnings beat by $0.05, revenue topped estimates - Investing.com Canada
InspireMD, Inc. (NSPR) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
InspireMD Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings call transcript: InspireMD Q4 2025: Revenue Surges, EPS Beats - Investing.com
InspireMD, Inc. Overview: CGuard Carotid Stent Technology, Business Strategy, and Market Leadership in Stroke Prevention 72 - Minichart
InspireMD Reports Strong Q4 2025 Growth and Expansion - TipRanks
FDA PMA and global expansion reshape InspireMD (NSPR) carotid focus - Stock Titan
InspireMD, Inc. (NSPR) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
InspireMD, Inc. Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
InspireMD Q4 net income USD -11.761 million - marketscreener.com
InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results - Bitget
INSPIREMD ($NSPR) Releases Q4 2025 Earnings - Quiver Quantitative
InspireMD (NSPR) revenue climbs 28% in 2025 as net loss widens - Stock Titan
InspireMD Q4 revenue rises 62%, beats estimates - TradingView
NSPR: Q4 2025 revenue surged 62% year-over-year, with 2026 revenue growth projected at up to 65% - TradingView
InspireMD, Inc. (NSPR) Announces Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
InspireMD Inc. Stock (NSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
InspireMD Inc. Stock (NSPR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gleason Shane Thomas | Chief Commercial Officer |
Jan 28 '26 |
Sale |
1.65 |
12,395 |
20,464 |
1,149,077 |
| Gleason Shane Thomas | Chief Commercial Officer |
Jan 22 '26 |
Sale |
1.57 |
8,411 |
13,239 |
1,166,253 |
| Gleason Shane Thomas | Chief Commercial Officer |
Jan 29 '26 |
Sale |
1.65 |
5,000 |
8,250 |
1,144,077 |
| Gleason Shane Thomas | Chief Commercial Officer |
Jan 27 '26 |
Sale |
1.66 |
4,781 |
7,956 |
1,161,472 |
| Gleason Shane Thomas | Chief Commercial Officer |
Jan 30 '26 |
Sale |
1.63 |
2,900 |
4,730 |
1,141,177 |
| Gleason Shane Thomas | Chief Commercial Officer |
Jan 20 '26 |
Sale |
1.59 |
2,955 |
4,710 |
1,192,257 |
| Gleason Shane Thomas | Chief Commercial Officer |
Jan 15 '26 |
Sale |
1.58 |
2,909 |
4,593 |
1,197,462 |
| Gleason Shane Thomas | Chief Commercial Officer |
Jan 16 '26 |
Sale |
1.61 |
2,250 |
3,627 |
1,195,212 |
| Gleason Shane Thomas | Chief Commercial Officer |
Feb 02 '26 |
Sale |
1.60 |
2,000 |
3,208 |
1,139,177 |
| Stuka Paul | Director |
Dec 09 '25 |
Buy |
1.81 |
5,073 |
9,182 |
391,628 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):